Article
Pharmacology & Pharmacy
Isabel Hamshaw, Marco M. D. Cominetti, Wing-Yee Lai, Mark Searcey, Anja Mueller
Summary: Cancer metastasis is a major cause of cancer-related death. The CXCR4 receptor and its ligand CXCL12 play important roles in promoting metastasis, making them attractive therapeutic targets. In this study, a novel CXCR4 antagonist was developed and used for CXCR4-based imaging. The results showed that these antagonists were non-toxic and effectively inhibited cancer cell migration and calcium release.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Immunology
Kimia Ghasemi, Kosar Ghasemi
Summary: Chemokines and their receptors play crucial roles in immune responses. CXCR4, a GPCR, interacts with SDF-1 to regulate multiple signaling pathways and has potential therapeutic value in cancer treatment. MSX-122, an orally available CXCR4 antagonist, shows promising anti-cancer properties, especially in treating metastatic cancers.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Yaru Yang, Jiayan Li, Wangrui Lei, Haiying Wang, Yunfeng Ni, Yanqing Liu, Huanle Yan, Yifan Tian, Zheng Wang, Zhi Yang, Shulin Yang, Yang Yang, Qiang Wang
Summary: Cancer is a complex disease caused by genetic mutations and/or epigenetic changes, and it poses the biggest challenge worldwide. Cytokines, particularly chemokines, play a significant role in various human cancers by affecting homeostasis, immune function, and facilitating cancer development stages such as invasion, metastasis, and angiogenesis. Specifically, chemokines such as CXCL12 and its receptors CXCR4 and CXCR7 exert extensive influence on tumor cell behavior, including proliferation, survival, angiogenesis, metastasis, and tumor microenvironment, making them crucial players in the initiation and progression of cancers such as leukemia, breast cancer, lung cancer, prostate cancer, and multiple myeloma. This review aims to summarize the recent research progress and future challenges related to the CXCL12-CXCR4/CXCR7 signaling axis in cancer, emphasizing the potential of utilizing CXCL12-CXCR4/CXCR7 as a biomarker or therapeutic target for cancer treatment and providing valuable insights for the development of targeted cancer therapies.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Cell Biology
Weilin Sun, Gang Ma, Li Zhang, Pengliang Wang, Nannan Zhang, Zizhen Wu, Yinping Dong, Fenglin Cai, Liqiao Chen, Huifang Liu, Han Liang, Jingyu Deng
Summary: ADAMTS9 in gastric cancer cells exerts inhibitory effects, with its decreased expression associated with malignant phenotypes and poor prognosis. Restoration of ADAMTS9 significantly suppressed the viability and motility of GC cells.
CELL DEATH & DISEASE
(2021)
Article
Multidisciplinary Sciences
Andrea S. Fung, Karen Kopciuk, Michelle L. Dean, Adrijana D'Silva, Shannon Otsuka, Alexander Klimowicz, Desiree Hao, Don Morris, D. Gwyn Bebb
Summary: Evidence suggests that overexpression of CXCR4 is associated with poor outcomes in stage IV NSCLC, especially in females. However, in early stage NSCLC patients, CXCR4 expression does not predict recurrence-free or overall survival, regardless of gender. Further exploration and clinical trials are needed to understand the mechanisms of CXCR4 expression during lung carcinogenesis.
Article
Oncology
Ruozheng Wei, Yuning Zhou, Chang Li, Piotr Rychahou, Shulin Zhang, William B. Titlow, Greg Bauman, Yuanyuan Wu, Jinpeng Liu, Chi Wang, Heidi L. Weiss, B. Mark Evers, Qingding Wang
Summary: This study identifies ketogenesis as a critical regulator of the tumor microenvironment in colorectal cancer and suggests the potential for ketogenic diets as a metabolic strategy to overcome immunosuppression and prolong survival.
Article
Chemistry, Medicinal
Charlotte Martin, Luis E. Gimenez, Savannah Y. Williams, Yu Jing, Yiran Wu, Charlie Hollanders, Olivier Van der Poorten, Simon Gonzalez, Kevin Van Holsbeeck, Santo Previti, Arthur Lamouroux, Suwen Zhao, Dirk Tourwe, Raymond C. Stevens, Roger D. Cone, Steven Ballet
Summary: The study focused on the structural features of MC4R antagonist peptide ligands, revealing key insights into structural features related to selectivity and providing a basis for designing more selective ligands.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Cell Biology
Shiqing Liu, Chengping Hu, Min Li, Jian An, Wolong Zhou, Jia Guo, Yao Xiao
Summary: This study reveals that estrogen receptor beta promotes non-small-cell lung cancer cell invasion through regulating the circ-TMX4/miR-622/CXCR4 signaling pathway. These findings provide a new target for the development of treatment strategies to suppress lung cancer progression.
CELL DEATH & DISEASE
(2022)
Article
Biology
Huizi Yao, Huimin Li, Jinyu Wang, Tao Wu, Wei Ning, Kaixuan Diao, Chenxu Wu, Guangshuai Wang, Ziyu Tao, Xiangyu Zhao, Jing Chen, Xiaoqin Sun, Xue-Song Liu
Summary: The analysis of copy number patterns of cancer genomes assists in developing a machine learning algorithm for accurately predicting homologous recombination deficiency (HRD) status. HRD renders cancer cells vulnerable to unrepaired double-strand breaks and is an important therapeutic target. Copy number alteration (CNA) can be extracted from various data sources and used for cost-effective HRD prediction. A gradient boosting machine model (HRDCNA) was built based on CNA features, identifying specific gene inactivation and providing a robust tool for HRD prediction.
COMMUNICATIONS BIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Tripti Khare, Marc Bissonnette, Sharad Khare
Summary: Chemokines like CXCL12 play a significant role in cancer growth and metastasis, with receptors like CXCR4 and CXCR7 being potential targets for treatment strategies in colorectal cancer. Targeting the CXCL12-CXCR4/CXCR7 axis shows promise in developing new therapies for CRC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Fei Kong, Huiyuan Bai, Ming Ma, Chen Wang, Haiyan Xu, Ning Gu, Yu Zhang
Summary: The utilization of a composite nanozyme to target and treat acute myeloid leukemia represents a potential therapeutic approach, alleviating the toxic side effects of chemotherapy and improving treatment efficacy.
Article
Immunology
Paola Antonello, Diego U. Pizzagalli, Mathilde Foglierini, Serena Melgrati, Egle Radice, Sylvia Thelen, Marcus Thelen
Summary: Chemotaxis is an essential process in tumors metastasis, and in this study, ACKR3 was found to control the migration of lymphoma cells in response to CXCL12. The interaction between LTB4 and CXCL12 enhances the migration of lymphoma cells, providing a novel mechanism for cell-to-cell-induced migration.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell Biology
Gary D. Luker, Jinming Yang, Ann Richmond, Stefania Scala, Claudio Festuccia, Margret Schottelius, Hans-Jurgen Wester, Johann Zimmermann
Summary: Signaling through CXCR4 regulates essential physiological processes and plays crucial roles in tumor growth, invasion, and metastasis. Animal models consistently demonstrate the importance of CXCR4 in cancer initiation and progression.
JOURNAL OF LEUKOCYTE BIOLOGY
(2021)
Article
Biology
Valentina Poltavets, Jessica W. Faulkner, Deepak Dhatrak, Robert J. Whitfield, Shaun R. McColl, Marina Kochetkova
Summary: The CXCR4 and CCR7 receptor ligands, CXCL12 and CCL19, cooperatively bind and selectively elicit synergistic signaling responses in invasive breast cancer cell lines and primary mammary human tumor cells. The presence of CXCR4-CCR7 heterodimers in advanced primary mammary mouse and human tumors directly correlates with the severity of the disease, and their forced heterodimerization leads to the acquisition of invasive phenotype in non-metastatic breast cancer cells. These findings establish the CXCR4-CCR7 receptor complex as a new functional unit responsible for the acquisition of breast cancer cell metastatic phenotype and a potential novel biomarker for invasive mammary tumors.
Article
Pharmacology & Pharmacy
Mahdieh Mehrpouri
Summary: CXCL12/CXCR4 and CXCL12/CXCR7 axes play a key role in hematopoiesis and their aberrant expression may lead to the development of leukemia. Various therapeutic interventions have been developed to target these axes in leukemic cells, showing promising results in pre-clinical and clinical studies.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)